David Livermore

Q: What Schools Are Affiliated With David Livermore

David Livermore is affiliated with the following schools: University of East Anglia, Hacettepe University, Imperial College London, University of Oxford, Cardiff University, University of Basel, Queen Mary University of London, Biozentrum University of Basel, University of Manchester

David Livermore 's AcademicInfluence.com Rankings

David Livermore

Biology

#2995

World Rank

#4649

Historical Rank

Microbiology

#86

World Rank

#107

Historical Rank

Neuroscience

#291

World Rank

#306

Historical Rank

biology Degrees

Download Badge

Biology

David Livermore 's Degrees

PhD Microbiology University of Oxford
Bachelors Biotechnology University of Manchester

Why Is David Livermore Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Livermore is professor of medical microbiology at the University of East Anglia. After working at the London Hospital Medical College from 1980 to 1997, he joined the Public Health Laboratory Service , and became director of its Antibiotic Resistance Monitoring and Reference Laboratory. He was appointed professor of medical microbiology at the University of East Anglia in 2011. His chief research has been on the evolution and epidemiology of antibiotic resistance.

(See a Problem?)

David Livermore 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study (2010) (2702)
beta-Lactamases in laboratory and clinical resistance (1995) (1983)
Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? (2002) (1418)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. (2013) (1293)
Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. (2011) (1117)
Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. (2006) (1031)
CTX-M: changing the face of ESBLs in Europe. (2006) (966)
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. (2012) (796)
Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. (2011) (791)
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. (2006) (727)
Has the era of untreatable infections arrived? (2009) (624)
Bacterial resistance: origins, epidemiology, and impact. (2003) (599)
Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. (2006) (575)
The emerging NDM carbapenemases. (2011) (571)
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. (2004) (536)
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. (2009) (493)
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction (2001) (480)
Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center (2004) (479)
Antibiotic resistance in staphylococci. (2000) (467)
The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter (2006) (452)
Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. (2009) (417)
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia (2013) (412)
Of Pseudomonas, porins, pumps and carbapenems. (2001) (411)
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. (2017) (407)
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin (1994) (403)
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens (2012) (395)
Infections caused by Gram-positive bacteria: a review of the global challenge. (2009) (375)
Carbapenemases: a problem in waiting? (2000) (344)
What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. (2011) (328)
Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis (2000) (326)
The need for new antibiotics. (2004) (325)
Detection of β-lactamase-mediated resistance (2001) (325)
Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System (2011) (322)
Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii (2001) (322)
CTX-M: changing the face of ESBLs in the UK. (2005) (299)
Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa (1992) (295)
Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. (2010) (294)
Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection (2019) (292)
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance (1994) (290)
Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece (2000) (284)
Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). (2001) (282)
Complete Nucleotide Sequences of Plasmids pEK204, pEK499, and pEK516, Encoding CTX-M Enzymes in Three Major Escherichia coli Lineages from the United Kingdom, All Belonging to the International O25:H4-ST131 Clone (2009) (282)
Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database (2007) (279)
Tigecycline: what is it, and where should it be used? (2005) (271)
Minimising antibiotic resistance. (2005) (266)
Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. (2001) (263)
Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance (2013) (260)
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. (2013) (257)
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. (2011) (255)
Discovery research: the scientific challenge of finding new antibiotics. (2011) (253)
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. (1996) (248)
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). (2002) (247)
Linezolid in vitro: mechanism and antibacterial spectrum. (2003) (247)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae (2010) (237)
IMP-4, a Novel Metallo-β-Lactamase from Nosocomial Acinetobacter spp. Collected in Hong Kong between 1994 and 1998 (2001) (233)
Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing (2017) (233)
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party† (2018) (226)
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. (2013) (221)
Fourteen years in resistance. (2012) (217)
Outbreak of Carbapenem-Resistant Acinetobacter baumannii Producing the OXA-23 Enzyme in Curitiba, Brazil (2003) (213)
Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. (2009) (210)
Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England (2006) (207)
Beta-lactamase-mediated resistance and opportunities for its control. (1998) (207)
Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. (2014) (206)
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. (2006) (203)
bla VIM-2 Cassette-Containing Novel Integrons in Metallo-β-Lactamase-Producing Pseudomonas aeruginosa and Pseudomonas putida Isolates Disseminated in a Korean Hospital (2002) (203)
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. (2000) (200)
Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. (2011) (197)
Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. (2011) (193)
Defining an extended‐spectrum β‐lactamase (2008) (185)
Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6 (1994) (184)
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. (2008) (182)
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. (1990) (181)
Epidemiology of antibiotic resistance (2000) (181)
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential (2004) (179)
Diverse Sequence Types of Klebsiella pneumoniae Contribute to the Dissemination of blaNDM-1 in India, Sweden, and the United Kingdom (2012) (178)
UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. (2008) (178)
Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7 (2002) (176)
Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. (2004) (173)
Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia (2004) (164)
Trends among pathogens reported as causing bacteraemia in England, 2004-2008. (2011) (163)
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. (2004) (163)
Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. (2007) (163)
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? (2010) (162)
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates (1990) (161)
In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. (2006) (159)
Properties and potential of ertapenem. (2003) (159)
Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. (2010) (159)
Worldwide emergence of carbapenem-resistant Acinetobacter spp. (1998) (158)
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa (1993) (156)
Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method (2000) (156)
Complexity and Diversity of Klebsiella pneumoniae Strains with Extended-Spectrum β-Lactamases Isolated in 1994 and 1996 at a Teaching Hospital in Durban, South Africa (2001) (155)
Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum beta-lactamases in the UK. (2008) (151)
Efflux Pumps, OprD Porin, AmpC β-Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients (2010) (151)
Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. (2006) (148)
Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? (2012) (144)
Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. (2008) (143)
Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria (2013) (139)
Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. (1995) (137)
Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. (2006) (137)
The impact of carbapenemases on antimicrobial development and therapy. (2002) (136)
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. (2007) (134)
AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. (2010) (133)
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. (2001) (133)
In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase (2015) (132)
Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. (2013) (131)
In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia (2001) (130)
Outbreak of Pseudomonas aeruginosa Infections with PER-1 Extended-Spectrum β-Lactamase in Warsaw, Poland: Further Evidence for an International Clonal Complex (2007) (130)
Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. (2000) (129)
Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units. (1998) (128)
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. (2008) (126)
Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. (2002) (125)
Emerging Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care Unit (2002) (123)
Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. (2016) (123)
Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999 (2002) (122)
Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital. (1992) (121)
Occurrence of OXA-58-Like Carbapenemases in Acinetobacter spp. Collected over 10 Years in Three Continents (2006) (120)
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011) (2013) (120)
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. (2008) (120)
Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. (2005) (118)
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. (2010) (118)
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods (1987) (117)
Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. (2019) (113)
Comparison of BD Phoenix, Vitek 2, and MicroScan Automated Systems for Detection and Inference of Mechanisms Responsible for Carbapenem Resistance in Enterobacteriaceae (2010) (113)
Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. (2009) (112)
β-Lactamase Lability and Inducer Power of Newer β-Lactam Antibiotics in Relation to Their Activity Against β-Lactamase-Inducibility Mutants of Pseudomonas aeruginosa (1987) (112)
Rapid Identification of Major Escherichia coli Sequence Types Causing Urinary Tract and Bloodstream Infections (2014) (111)
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. (2008) (111)
Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. (2012) (110)
OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'. (2015) (108)
Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002 (2003) (106)
Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. (2010) (106)
Detection of beta-lactamase-mediated resistance. (2001) (105)
Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water. (2011) (105)
Carbapenem antibiotics for serious infections (2012) (104)
Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals (2007) (104)
OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa (1999) (104)
The threat from the pink corner (2003) (104)
Can better prescribing turn the tide of resistance? (2004) (104)
Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. (2006) (103)
Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. (1996) (102)
Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. (2011) (102)
Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. (2006) (101)
Are SHV β-Lactamases Universal in Klebsiella pneumoniae? (2000) (101)
Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. (1998) (100)
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii (2016) (100)
Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? (2013) (99)
OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain (1997) (99)
Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles (2017) (99)
Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. (1995) (98)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria (2017) (98)
Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases (2004) (96)
Effect of subinhibitory concentrations of antibiotics on mutation frequency in Streptococcus pneumoniae. (2006) (94)
Surveillance of antimicrobial resistance (1998) (94)
Antibiotic resistance: location, location, location. (2007) (92)
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. (1990) (91)
Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK. (2010) (90)
Variation in the genetic environments of bla(CTX-M-15) in Escherichia coli from the faeces of travellers returning to the United Kingdom. (2011) (88)
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. (2010) (88)
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? (2000) (88)
Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. (2013) (87)
Endemic Carbapenem Resistance Associated with OXA-40 Carbapenemase among Acinetobacter baumannii Isolates from a Hospital in Northern Spain (2002) (86)
Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. (2012) (83)
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. (2009) (83)
Activity of Ertapenem (MK-0826) versusEnterobacteriaceae with Potent β-Lactamases (2001) (81)
Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. (2009) (81)
Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against β-lactam antibiotics (2014) (81)
The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients (2013) (81)
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline (2020) (81)
Determinants of the activity of β-lactamase inhibitor combinations (1993) (80)
Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. (2008) (80)
OXA-16, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, from Two Pseudomonas aeruginosa Isolates (1998) (80)
Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI) (2015) (79)
Temocillin revived. (2009) (79)
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. (2009) (78)
Introduction: the challenge of multiresistance. (2007) (77)
Plasmids Imparting Sulfonamide Resistance in Escherichia coli: Implications for Persistence (2008) (76)
Emergence of Enterobacteriaceae Isolates Producing CTX-M Extended-Spectrum β-Lactamase in Austria (2006) (76)
In Vitro Activities of Antibiotics Alone and in Combination against Brucella melitensis at Neutral and Acidic pHs (1999) (76)
Multiresistant serotype O 12 Pseudomonas aeruginosa: evidence for a common strain in Europe (1989) (75)
Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq. (2006) (75)
Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa (1995) (74)
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. (2010) (74)
Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. (2008) (73)
Defining an extended-spectrum beta-lactamase. (2008) (72)
Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. (2008) (72)
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa (1993) (72)
Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. (2006) (71)
Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. (2008) (71)
Dominance of international 'high-risk clones' among metallo-β-lactamase-producing Pseudomonas aeruginosa in the UK. (2015) (70)
Beta-lactamase inhibitors: agents to overcome bacterial resistance. (1998) (70)
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. (2009) (70)
Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method. (2004) (69)
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. (2005) (69)
Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. (2010) (68)
Are all beta-lactams created equal? (1996) (68)
Complete nucleotide sequence of the IncN plasmid pKOX105 encoding VIM-1, QnrS1 and SHV-12 proteins in Enterobacteriaceae from Bolzano, Italy compared with IncN plasmids encoding KPC enzymes in the USA. (2010) (67)
Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum beta-lactamases in the UK. (2007) (66)
Mechanisms of resistance to beta-lactam antibiotics. (1991) (66)
National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. (1995) (65)
Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss. (2007) (65)
Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. (2010) (65)
OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014 (2017) (65)
Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK. (2011) (64)
NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. (2014) (64)
Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. (2000) (64)
Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa. (1984) (64)
Antibiotic resistance in bacteria from magpies (Pica pica) and rabbits (Oryctolagus cuniculus) from west Wales. (2001) (63)
A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus. (2013) (63)
Mechanisms of resistance to β-lactam antibiotics (1991) (62)
Balkan NDM-1: escape or transplant? (2011) (58)
Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. (2008) (58)
Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and -susceptible strains of Pseudomonas aeruginosa. (1984) (57)
Can β‐lactams be re‐engineered to beat MRSA? (2006) (56)
OXA-1 &bgr;-lactamase and non-susceptibility to penicillin/&bgr;-lactamase inhibitor combinations among ESBL-producing Escherichia coli (2018) (56)
Sulfonamide Resistance in Haemophilus influenzae Mediated by Acquisition of sul2 or a Short Insertion in Chromosomal folP (2002) (56)
beta-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance. (1987) (56)
Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates (2011) (55)
Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). (2012) (54)
Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases. (1991) (54)
Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. (2008) (53)
Efficacies of calcium–EDTA in combination with imipenem in a murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase (2013) (53)
Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum beta-lactamases. (2010) (52)
Detection of Oxazolidinone-Resistant Enterococcus faecalis and Enterococcus faecium Strains by Real-Time PCR and PCR-Restriction Fragment Length Polymorphism Analysis (2002) (52)
CTX-M extended-spectrum β-lactamase arrives in the UK (2003) (52)
Activity of mecillinam against ESBL producers in vitro. (2006) (51)
Carbapenemases of Chryseobacterium(Flavobacterium) meningosepticum: Distribution ofblaB and Characterization of a Novel Metallo-β-Lactamase Gene, blaB3, in the Type Strain, NCTC 10016 (2000) (50)
Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. (2006) (50)
Prevalence and antimicrobial resistance among Gram-negative pathogens in Saudi Arabia (2014) (50)
Carbapenem-Resistant Klebsiella pneumoniae in Singapore Producing IMP-1 β-Lactamase and Lacking an Outer Membrane Protein (2001) (49)
IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. (2002) (49)
Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae (2019) (48)
Do β-lactamases trap cephalosporins? (1985) (47)
Extended-spectrum beta-lactamase detected in E coli recovered from calves in Wales. (2005) (47)
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. (1995) (47)
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16 (2018) (46)
False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. (2011) (46)
Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. (1997) (45)
Susceptibility of Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern (1994) (45)
Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. (2011) (45)
Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. (2013) (44)
Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England. (2008) (44)
In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci (2007) (44)
Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. (2000) (44)
Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. (2010) (44)
Mechanisms of Resistance to Cephalosporin Antibiotics (2012) (44)
Detection of CTX-M-15 extended-spectrum β-lactamase in the United Kingdom (2003) (44)
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa (2018) (43)
Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014 (2016) (43)
Early (2008-2010) hospital outbreak of Klebsiella pneumoniae producing OXA-48 carbapenemase in the UK. (2013) (43)
Population structure of Escherichia coli causing bacteraemia in the UK and Ireland between 2001 and 2010. (2016) (42)
Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. (2003) (42)
High prevalence of acquired quinolone-resistance genes among Enterobacteriaceae from Saudi Arabia with CTX-M-15 β-lactamase. (2012) (42)
Acquired carbapenemases. (1997) (42)
Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing beta-lactamase Sme-1, and comparison of this regulator with other beta-lactamase regulators (1995) (42)
Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic Stewardship (2013) (42)
In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. (2008) (42)
Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase. (1997) (41)
Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. (1991) (41)
Future directions with daptomycin. (2008) (41)
Kucers' The use of antibiotics (2011) (40)
Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. (1990) (40)
Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. (2013) (40)
Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. (2015) (40)
Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. (2004) (39)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria (2020) (39)
False-positive extended-spectrum β-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 β-lactamase (2004) (39)
Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. (2010) (39)
Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. (2005) (39)
The zeitgeist of resistance. (2007) (38)
Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae. (1993) (38)
Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii (1988) (38)
Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. (1993) (38)
Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae. (1988) (38)
Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. (2008) (38)
Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. (2003) (38)
Evaluation of the chromogenic Cica-β-Test for detecting extended-spectrum, AmpC and metallo-β-lactamases (2007) (38)
Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. (2013) (37)
Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008: Metallo-β-lactamases among Enterobacteriaceae from routine samples (2011) (36)
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. (1997) (36)
Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing. (2000) (36)
Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. (1989) (35)
In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases. (1981) (35)
In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. (2003) (35)
National survey of antibiotic resistance in Pseudomonas aeruginosa. (1984) (35)
Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? (2004) (35)
Interactions of meropenem with Class I chromosomal β-lactamases (1989) (35)
Detection of PSE-2 beta-lactamase in enterobacteria (1984) (34)
Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit. (1998) (34)
In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK. (2014) (34)
Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. (2010) (33)
Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia (2012) (33)
Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. (1999) (33)
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants (2015) (33)
Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'. (2001) (33)
Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia (2012) (33)
Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108 717 clinical isolates from primary, secondary and tertiary care patients in London (2014) (33)
Doripenem: antimicrobial profile and clinical potential. (2009) (32)
Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008. (2011) (32)
Characterization of NPS-1, a novel plasmid-mediated beta-lactamase, from two Pseudomonas aeruginosa isolates (1986) (32)
Rapid Diagnosis of Lower Respiratory Infection using Nanopore-based Clinical Metagenomics (2018) (32)
Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland (2009) (31)
Antibiotic uptake and transport by bacteria. (1990) (31)
Effects of CO2 and pH on inhibition of TEM-1 and other beta-lactamases by penicillanic acid sulfones (1992) (31)
Activity of ertapenem against Neisseria gonorrhoeae. (2004) (31)
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. (1999) (31)
Early onset Morganella morganii sepsis in a newborn infant with emergence of cephalosporin resistance caused by depression of AMPC beta-lactamase production.. (2006) (31)
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. (2012) (30)
AmpC induction by ceftaroline. (2010) (30)
Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. (2001) (30)
Plasmid-mediated production of class I (AmpC) beta-lactamase by two Klebsiella pneumoniae isolates from the UK. (1995) (30)
Distribution of β-lactamases in carbapenem-non-susceptible Acinetobacter baumannii in Riyadh, Saudi Arabia. (2014) (30)
Impact of a clonal outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK. (2011) (30)
Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. (2006) (30)
Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland. (2003) (29)
Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae (2018) (29)
Bacterial resistance to carbapenems. (1995) (28)
Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. (2006) (28)
Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK. (2002) (28)
Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing. (2000) (28)
Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. (2015) (28)
Fusidic-acid use and resistance (2002) (27)
Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. (2014) (27)
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. (2009) (27)
Which cephalosporin for gonorrhoea? (2004) (27)
β -Lactamases- the Threat Renews (2009) (27)
PSEUDOMONAS AERUGINOSA ISOLATES WITH MODIFIED BETA-LACTAMASE INDUCIBILITY: EFFECTS ON BETA-LACTAM SENSITIVITY (1982) (27)
Dissemination of pCT-Like IncK Plasmids Harboring CTX-M-14 Extended-Spectrum β-Lactamase among Clinical Escherichia coli Isolates in the United Kingdom (2012) (26)
Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. (2015) (26)
A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum beta-lactamases. (2007) (26)
Activity of faropenem against cephalosporin-resistant Enterobacteriaceae. (2007) (26)
Clavnlanate and β-lactamase induction (1989) (26)
Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. (2004) (26)
Determinants of the activity of beta-lactamase inhibitor combinations. (1993) (26)
The 2018 Garrod Lecture: Preparing for the Black Swans of resistance (2018) (26)
Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory (1998) (25)
Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. (1995) (25)
Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its “Sell-By Date” in an Era of New Antibiotics and Regional Carbapenemase Epidemiology (2020) (25)
Invalidity for Pseudomonas aeruginosa of an accepted model of bacterial permeability to beta-lactam antibiotics (1991) (25)
Increasing Hospitalizations and General Practice Prescriptions for Community-onset Staphylococcal Disease, England (2008) (24)
Kinetics and significance of the activity of the Sabath and Abrahams' beta-lactamase of Pseudomonas aeruginosa against cefotaxime and cefsulodin. (1983) (24)
National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia (2014) (24)
Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK. (2010) (24)
Radiolabelling of penicillin-binding proteins (PBPs) in intact Pseudomonas aeruginosa cells: consequences of beta-lactamase activity by PBP-5. (1987) (24)
Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. (1999) (24)
Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases. (2000) (24)
KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region. (2016) (24)
Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. (2015) (23)
Klebsiella pneumoniae isolate from South Africa with multiple TEM, SHV and AmpC beta-lactamases. (2004) (23)
WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D &bgr;-lactamases (2017) (23)
In Vitro Activity of Cephalosporin RWJ-54428 (MC-02479) against Multidrug-Resistant Gram-Positive Cocci (2002) (23)
Evidence of dimerisation among class D β-lactamases: kinetics of OXA-14 β-lactamase (2001) (23)
Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases. (2003) (22)
CTX-M extended-spectrum beta-lactamase arrives in the UK. (2003) (22)
'Covalent trapping' and latamoxef resistance in beta-lactamase-derepressed Pseudomonas aeruginosa. (1987) (22)
Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens (2018) (22)
Living with ESBLs (2007) (22)
SHV-13, a Novel Extended-Spectrum β-Lactamase, in Klebsiella pneumoniae Isolates from Patients in an Intensive Care Unit in Amsterdam (2000) (22)
Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae. (2006) (22)
Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. (2003) (22)
Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000 (2001) (21)
In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. (1994) (21)
β-Lactamases of Pseudomonas aeruginosa (1982) (21)
Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test (2020) (21)
β-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to β-lactamase inhibitor combinations (1994) (21)
Effect of media composition on the susceptibility of Xanthomonas mahophilia to β-lactam antibiotics (1991) (21)
A one-year survey of Neisseria gonorrhoeae isolated from patients attending an east London genitourinary medicine clinic: antibiotic susceptibility patterns and patients' characteristics. (1995) (20)
Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . (1991) (20)
Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study (2020) (20)
Behaviour of TEM-1 beta-lactamase as a resistance mechanism to ampicillin, mezlocillin and azlocillin in Escherichia coli. (1986) (20)
Antibiotic resistance during and beyond COVID-19 (2021) (20)
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. (2020) (20)
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial. (2020) (20)
Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated? (2001) (20)
False-positive extended-spectrum beta-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 beta-lactamase. (2004) (20)
Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus. (2006) (19)
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. (2007) (19)
Comparison of the β-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa (1981) (19)
Expression of H1 outer-membrane protein of Pseudomonas aeruginosa in relation to sensitivity to EDTA and polymyxin B. (1987) (19)
Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999. (2000) (19)
Antibacterial usage in English NHS hospitals as part of a national Antimicrobial Stewardship Programme. (2014) (19)
Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. (2011) (19)
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial (2018) (18)
Of stewardship, motherhood and apple pie. (2014) (18)
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales. (2001) (18)
In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative organisms and its stability to their beta-lactamases. (1981) (18)
Dissociation of surface properties and "intrinsic" resistance to beta lactams in Pseudomonas aeruginosa. (1986) (18)
ISEcp1-mediated transposition of linked blaCTX-M-3 and blaTEM-1b from the IncI1 plasmid pEK204 found in clinical isolates of Escherichia coli from Belfast, UK. (2011) (18)
Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. (1987) (18)
New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080. (2016) (18)
Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. (2003) (18)
Can beta-lactams be re-engineered to beat MRSA? (2006) (18)
Interactions of β-Lactamases with Sanfetrinem (GV 104326) Compared to Those with Imipenem and with Oral β-Lactams (1998) (17)
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. (2021) (17)
Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern. (1994) (17)
In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa (1985) (17)
Performance of the Oxoid M.I.C.Evaluator™ Strips compared with the Etest® assay and BSAC agar dilution (2010) (17)
In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. (2007) (17)
Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. (2004) (17)
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections. (2019) (17)
Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework (2021) (17)
'CRE, CRO, CPE and CPO': terminology past its 'sell-by-date' in an era of new antibiotics and regional carbapenemase epidemiology. (2020) (16)
Role of beta-lactamase and impermeability in the resistance of Pseudomonas aeruginosa. (1989) (16)
PSE-4 beta lactamase: a serotype-specific enzyme in Pseudomonas aeruginosa. (1985) (16)
AmpC &bgr;-lactamase induction by avibactam and relebactam (2017) (16)
Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study (2017) (16)
Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study (2017) (16)
β-Lactamases: quantity and resistance (1997) (16)
Genetic environment of metallo-β-lactamase genes in Pseudomonas aeruginosa isolates from the UK. (2015) (16)
Permeation of β-Lactam Antibiotics into Escherichia coli, Pseudomonas aeruginosa, and Other Gram-Negative Bacteria (1988) (15)
beta-Lactamases: quantity and resistance. (1997) (15)
Rapid and Point-of-Care Testing in Respiratory Tract Infections: An Antibiotic Guardian? (2020) (15)
In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. (2002) (15)
Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance. (1994) (15)
Pseudomonas aeruginosa beta-lactamase as a defence against azlocillin, mezlocillin and piperacillin. (1984) (15)
Mechanisms by which imipenem may overcome resistance in gram-negative bacilli. (1986) (14)
Intensivists’ beliefs about rapid multiplex molecular diagnostic testing and its potential role in improving prescribing decisions and antimicrobial stewardship: a qualitative study (2021) (14)
A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study (2017) (14)
Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics. (1991) (14)
Nationwide Survey of CTX-M-Type Extended-Spectrum β-Lactamases among Klebsiella pneumoniae Isolates in Slovenian Hospitals (2008) (14)
The Difficulties of Identifying and treating Enterobacterales with OXA-48-like carbapenemases. (2019) (14)
Activity of temocillin and other penicillins against beta-lactamase-inducible and -stably derepressed enterobacteria. (1988) (14)
Evaluation of the chromogenic Cica-beta-Test for detecting extended-spectrum, AmpC and metallo-beta-lactamases. (2007) (14)
Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems. (1990) (13)
Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. (2021) (13)
Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin. (1994) (13)
Diversity of klebsiellae with extended-spectrum beta-lactamases at a Turkish university hospital. (1992) (13)
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. (2001) (13)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model (2017) (13)
Hydrolytic model for cefotaxime and ceftriaxone resistance in beta-lactamase-derepressed Enterobacter cloacae. (1986) (13)
Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams. (1990) (13)
Class D β-Lactamases (2007) (13)
Detection of CTX-M-15 extended-spectrum beta-lactamase in the United Kingdom. (2003) (13)
Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates. (1998) (12)
Overstretching the mutant prevention concentration. (2003) (12)
Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint. (2015) (12)
Development of high-level ceftazidime resistance via single-base substitutions of blaCTX-M-3 in hyper-mutable Escherichia coli. (2006) (12)
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. (2013) (12)
OXA-li, anExtended-Spectrum Variant ofOXA-10(PSE-2) ,-Lactamase fromPseudomonas aeruginosa (1993) (12)
beta-Lactamases- the Threat Renews. (2009) (12)
Prevalence of ciprofloxacin‐resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK (2015) (12)
Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa (2015) (12)
Effect of inoculum size on the in-vitro susceptibility to β-lactam antibiotics of Moraxella catarrhalis isolates of different β-lactamase types (1994) (11)
Mechanisms of chloramphenicol resistance in Haemophilus influenzae in the United Kingdom. (1988) (11)
Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance (2017) (11)
Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context. (2013) (11)
Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance (2017) (11)
New Delhi metallo-β-lactamase 1 – Authors' reply (2010) (11)
Selection and transformation of non-β-lactamase-mediated insusceptibility of β-lactams in Haemophilus influenzae: lack of cross-resistance between carbapenems and other agents (1990) (10)
Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph (2009) (10)
SHV-14, a Novel β-Lactamase Variant inKlebsiella pneumoniae Isolates from Nijmegen, The Netherlands (2001) (10)
Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes. (2008) (9)
Evidence of dimerisation among class D beta-lactamases: kinetics of OXA-14 beta-lactamase. (2001) (9)
Development of extended-spectrum activity in TEM beta-lactamases in hyper-mutable, mutS Escherichia coli. (2006) (9)
Mutation frequency in antibiotic-resistant and -susceptible isolates of Streptococcus pneumoniae. (2010) (9)
Increasing prevalence of methicillin resistance amongst Staphylococcus aureus blood culture isolates. (1999) (9)
Quality of antimicrobial susceptibility testing in the UK: a Pseudomonas aeruginosa survey revisited. (1999) (8)
Evolution of β-lactamase inhibitors (1994) (8)
High-level beta-lactam resistance in strains of Streptococcus pneumoniae isolated in the UK. (1998) (8)
Sensitivity testing of ciprofloxacin for Pseudomonas aeruginosa. (1997) (8)
Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines (2018) (7)
Interactions of meropenem with class I chromosomal beta-lactamases. (1989) (7)
Characterization of b -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline 1 avibactam (NXL104) (2012) (7)
Detection of qnrA among Enterobacteriaceae from South-East England with extended-spectrum and high-level AmpC beta-lactamases. (2007) (7)
Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base? (2018) (7)
OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline (2022) (7)
Clavulanate and beta-lactamase induction. (1989) (7)
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. (2022) (6)
Extraction of beta-lactamase from Moraxella catarrhalis. (1994) (6)
In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases. (1981) (6)
CLASS I β-LACTAMASE EXPRESSION IN PSEUDOMONAS AERUGINOSA AND CEPHALOSPORIN RESISTANCE (1986) (6)
Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics. (1988) (6)
LXA-1: a new plasmid-mediated β-lactamase giving low-level resistance (1988) (6)
Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types. (1994) (6)
Activity of the oxazolidinones AZD2563 and linezolid against Corynebacterium jeikeium and other Corynebacterium spp. (2003) (6)
First isolation of a CTX-M-3 β-lactamase producer in the United Kingdom (2004) (6)
Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance. (2018) (6)
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. (2020) (6)
Original articles Laboratory mutants of OXA-10 ‚-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa (1999) (6)
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. (2021) (5)
Unusual tazobactam-sensitive AmpC-lactamase from two Escherichia coli isolates (1998) (5)
Zinc ions and medium-dependent susceptibility to beta-lactams in Xanthomonas maltophilia. (1994) (5)
beta-Lactamases of Pseudomonas aeruginosa. (1991) (5)
Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response. (2012) (5)
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales. (2021) (5)
Do beta-lactamases 'trap' cephalosporins? (1985) (5)
Effects of β-lactamase induciblilty and derepression on the activity of cefepime and cefpirome against Gram-negative bacteria (1993) (5)
Permeation of beta-lactam antibiotics into Escherichia coli, Pseudomonas aeruginosa, and other gram-negative bacteria. (1988) (5)
Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563. (2004) (5)
Effects of low temperature and high salt on the activity of the novel carbapenem PZ-601 (SMP-601) against methicillin-resistant Staphylococcus aureus. (2008) (5)
Diagnosis of Lower Respiratory Tract Infections using nanopore sequencing (2018) (5)
Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus. (1994) (5)
Management of Multiple Drug-Resistant Infections (2004) (5)
Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams. (1998) (5)
Cephalosporin resistance in Pseudomonas aeruginosa, with special reference to the proposed trapping of antibiotics by beta-lactamase. (1985) (4)
Selection and transformation of non-beta-lactamase-mediated insusceptibility to beta-lactams in Haemophilus influenzae: lack of cross-resistance between carbapenems and other agents. (1990) (4)
P1025 Isolation of quinolone-resistant CTX-M-producing Escherichia coli from raw chicken meat sold in retail outlets in the West Midlands, UK (2007) (4)
Nalidixic acid-susceptible, ciprofloxacin-resistant Neisseria gonorrhoeae strain in the UK. (2005) (4)
Interactions of FCE 22101 with Class I β-lactamases (1989) (4)
Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias (2021) (4)
Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase. (1992) (4)
Facing antibiotic resistance. (2001) (4)
PTX 2416, a dihydroxypyridone monobactam, vs Pseudomonas aeruginosa strains with characterised resistances (2003) (4)
Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints. (2008) (4)
Two cases of import ation of New Delhi Metallo-β-lactamase 1 into Northern Ireland (2012) (4)
First isolation of a CTX-M-3 beta-lactamase producer in the United Kingdom. (2004) (4)
Living with ESBLs. Introduction. (2008) (4)
Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci. (2014) (4)
Antimicrobial Resistance in Bacteria, C.F. Amábile-Cuevas (Ed.). Horizon Bioscience, Wymondham, UK (2007), 201 pp., ISBN: 978-1-904933-24-3 (2007) (3)
In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii isolates from the UK (2020) (3)
BSAC Bacteraemia Resistance Surveillance Update 2005 (2007) (3)
Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria (2021) (3)
INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care—study protocol for a multicentre randomised controlled trial (2021) (3)
beta-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to beta-lactamase inhibitor combinations. (1994) (3)
beta-Lactamases of Pseudomonas aeruginosa. (1982) (3)
A review of health economic models exploring and evaluating treatment and management of Hospital-Acquired Pneumonia (HAP) and Ventilator Associated pneumonia (VAP). (2020) (3)
β-Lactamase Inhibitors: Agents to Overcome Bacterial Resistance (1998) (3)
Laboratory detection of bacteria with extended-spectrum beta-lactamases (2004) (3)
Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004. (2005) (3)
Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria (2018) (3)
Detecting vancomycin-intermediate Staphylococcus aureus: increased vigilance required by European microbiologists (1998) (3)
Decreased susceptibility to cephalosporins among gonococci? Authors' reply. (2014) (3)
P864 Complete nucleotide sequence of pEK499, a multidrug-resistance plasmid from the UK's most prevalent Escherichia coli strain with CTX-M-15 β-lactamase (2007) (3)
What's left in the cupboard? Older antimicrobials for treating gonorrhoea. (2021) (3)
P1348 Prevalence of an epidemic ESBL-producing Escherichia coli strain in LTCFs in Belfast (2007) (2)
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy (2020) (2)
Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. (1993) (2)
Dissociation of surface properties and ” intrinsic ” resistance top lactams in Pseudornonas aeruginosa (2008) (2)
COVID-19 vaccination and HIV-1 acquisition (2022) (2)
AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications (2022) (2)
Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al. (2018) (2)
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential (2010) (2)
Accuracy of routine susceptibility testing of Streptococcus pneumoniae in England and Wales. (2001) (2)
UK General Practice Research Database infections: retrospective cohort study with the complications of common respiratory tract Protective effect of antibiotics against serious (2008) (2)
Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution. (2022) (2)
In-vitro activity of tigemonam, an oral monobactam, against gram-negative rods, including variants in beta-lactamase-production. (1989) (2)
Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance Programme. (2021) (2)
Resistance to trimethoprim in Haemophilus influenzae (1991) (2)
Mechanisms and clinical significance of resistance to new beta-lactam antibiotics. (1990) (2)
Multidrug-resistant (MDR) Gram-negative bacteria information leaflets. (2016) (2)
Trapping and hydrolysis of latamoxef by β-lactamase in Pseudomonas aeruginosa (1989) (2)
Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa. (1981) (2)
Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy (2016) (2)
with Activity against Gram-negative Bacteria (2013) (2)
Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method. (2010) (1)
Leading article Acquired carbapenemases (1997) (1)
Activity of gemifloxacin against invasive and multi-resistant Streptococcus pneumoniae isolates collected in the UK. (2003) (1)
Reaction products of chloramphenicol acetyltransferases from enterobacteria and Haemophilus influenzae. (1989) (1)
KS3-1 NDM beta-lactamases; global impact (2013) (1)
Typing and epidemiological surveillance show that UK bloodstream Escherichia coli with extended-spectrum β-lactamases correspond to human gut strains, but not those from dinner (2019) (1)
In Vitro Activity of Ceﬁderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria (2020) (1)
Dependence of the interaction of ceftazidime and gentamicin against Pseudomonas aeruginosa on the bacterial growth-rate. (1991) (1)
Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003. (2005) (1)
Disagreements between disc diffusion, and MIC-based susceptibility categorizations of ertapenem versus ESBL producers. (2005) (1)
pH effects on the inhibition of extended-spectrum and classical TEM beta-lactamases by penicillanic acid sulphones. (1997) (1)
LB2304. INHALE WP3: Results of a multi-centre randomised controlled trial (INHALE) testing the utility of rapid multiplex PCR at point-of-care for the antibiotic management of hospital-acquired and ventilator-associated pneumonia in critical care. (2022) (1)
S287 Should all carbapenems be viewed the same (2007) (1)
Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. (2021) (1)
The role of ISAba1in expression of OXA carbapenemase genes inAcinetobacterbaumannii (2006) (1)
Intensivists’ beliefs about rapid multiplex molecular diagnostic testing and its potential role in improving prescribing decisions and antimicrobial stewardship: a qualitative study (2021) (0)
WITHDRAWN: Emergence of Epidemic Multi-Resistant Escherichia Coli Expressing Both CTX-M and Acquired CMY-2-Like Amp C Beta-Lactamases (2006) (0)
Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection (2019) (0)
Resistance trends among Enterobacterales from bacteraemias in the UK and Ireland, 2007 - 2017 (2020) (0)
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole - A Randomised Controlled Trial (2020) (0)
Leading article Of Pseudomonas, porins, pumps and carbapenems (2001) (0)
Interactions of FCE 22101 with class I beta-lactamases. (1989) (0)
Surveillance of bacteraemia in England and Wales 1990 to 1997 (1999) (0)
WITHDRAWN: Activity of temocillin vs. Prevalent esbland AMPC – producing enterobacteriaceae from SE England (2006) (0)
Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response. (2019) (0)
Evolution of beta-lactamase inhibitors. (1994) (0)
University of Birmingham Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis (2020) (0)
Trapping and hydrolysis of latamoxef by beta-lactamase in Pseudomonas aeruginosa. (1989) (0)
Real-time PCR for detection of the O25b-ST131 clone of and its CTX-M-15-like extended-spectrum -lactamases (2020) (0)
Ternary complex of E .coli leucyl-tRNA synthetase, tRNA(Leu) and the benzoxaborole AN3017 in the editing conformation (2013) (0)
Milestones in Drug Therapy. Fluoroquinolone Antibiotics: Ronald AR, Low DE (Eds.), Birkhauser, Basel, ISBN 3-7643-6591-9 (2004) (0)
P1647 Evaluation of Etests for determining tigecycline MICs by BSAC methodology (2007) (0)
National and international surveillance of antibiotic resistance 1 (2016) (0)
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole ( EME-TIPAC ) (2018) (0)
Effects of beta-lactamase inducibility and derepression on the activity of cefpirome against gram-negative bacteria. (1993) (0)
Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19? (2022) (0)
The Biology of Acinetobacter (1992) (0)
Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT (2021) (0)
Globalisation of antibiotic resistance (2016) (0)
Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales (2022) (0)
Methods in Molecular Medicine. Antibiotic Resistance, Methods and Protocols S. H. Gillespie, Ed. Humana Press, Totowa, NJ, 2001. ISBN 0-89603-777-0. $89.50. (2001) (0)
Does the resistance epidemiology demand new antibiotics (2002) (0)
Antimicrobial Chemotherapy. Amyes, Thomson, Miles and Tillotson. Pp. 68. London: Martin Dunitz, 1997. £9.95. ISBN 1 875317 389 4. (1997) (0)
, in the Type Strain , NCTC 10016 , blaB 3-Lactamase Gene , β a Novel Metallo-and Characterization of blaB Distribution of : meningosepticum ) Flavobacterium ( Chryseobacterium Carbapenemases (2000) (0)
Title: Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: a randomized clinical trial Subtitle: The EME-TIPAC study (2020) (0)
contributing factor to beta-lactam resistance. Pseudomonas aeruginosa: active efflux as a Role of efflux pump(s) in intrinsic resistance of (2013) (0)
In-vitro interactions of FCE 22101 with aminoglycosides against gram-negative rods. (1989) (0)
Ternary complex of E .coli leucyl-tRNA synthetase, tRNA(Leu) and the benzoxaborole AN3016 in the editing conformation (2013) (0)
Pseudomonas aeruginosa ST 357 with VEB ESBLs in the UK : relatedness and 2 resistance 3 4 (2018) (0)
Emerging Resistance among Gram-Negative Pathogens: State of the Challenge (2011) (0)
Introduction to Session 3 (1988) (0)
P676 Epidemiology of hospital-acquired Klebsiella pneumoniae producing CTX-M β-lactamases in Slovenia (2007) (0)
From Bench to Bedside Trialling the Future of Anti-infectives (2014) (0)
Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to XDR-Pseudomonas aeruginosa (2019) (0)
Activity of aztreonam/avibactam against metallo-β-Lactamase-producing Enterobacterales from the UK: impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli. (2023) (0)
Ternary complex of E .coli leucyl-tRNA synthetase, tRNA(Leu) and the benzoxaborole AN3213 in the editing conformation (2013) (0)
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia (2014) (0)
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07--authors' response. (2013) (0)
PENICILLIN-BINDING PROTEINS, PORINS A N D OUTER-MEMBRANE PERMEABILITY OF CARBENICILLIN- RESISTANT AND -SUSCEPTIBLE STRAINS OF PSEUDOMONAS AERUGINOSA (2008) (0)
P045 Strain and antibiogram changes, over time, in paediatric cystic fibrosis patients colonised with Pseudomonas aeruginosa (2018) (0)
P1011 Carbapenem resistance in an epidemic CTX-M-15 β-lactamase-producing Escherichia coli strain in the United Kingdom (2007) (0)
WITHDRAWN: What is the Clinical Relevance of Laboratory Reported Antibiotic Resistance to Trimethoprim in Primary Care Urinary Tract Infections? (2006) (0)
Macrolide Antibiotics (Milestones in Drug Therapy series) (2003) (0)
TITLE Rapid and Point of Care Testing ( POCT ) in Respiratory Tract Infections : An Antibiotic Guardian ? (2020) (0)
The Biology of Acinetobacter: Edited by K. J. Towner, E. Bergogne-Berezin and C.A. Fewson, 1991. ISBN 0-306043902-6. Plenum Press. New York. Pp. 451. $105. (1992) (0)
Does molecular antibiotic resistance testing improve diagnostics and standard of care ? (2013) (0)
Dissemination of NDM-1 – Authors' reply (2012) (0)
National and international surveillance of antibiotic resistance 2 (2016) (0)
Antibiotic Policies: Fighting Resistance, I.M. Gould, Jos Van Der Meer (Eds.). Springer Bioscience, New York (2007), 284 pp., ISBN-13: 978-0-387-70840-9, $140.00/£88 50 (2008) (0)
Brief reports Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina (1999) (0)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with 1 Cefepime in an In Vitro Infection Model 2 3 Running title : PK-PD of Tazobactam (2017) (0)
Overview of the current status of antimicrobial resistance (2021) (0)

This paper list is powered by the following services:

Other Resources About David Livermore

en.wikipedia.org

What Schools Are Affiliated With David Livermore ?

David Livermore is affiliated with the following schools:

David Livermore 's Academic­Influence.com Rankings

David Livermore 's Degrees

Why Is David Livermore Influential?

David Livermore 's Published Works

Published Works

Other Resources About David Livermore

What Schools Are Affiliated With David Livermore ?

David Livermore 's AcademicInfluence.com Rankings